Gilead hepatitis C drug patent faces European challenge

LONDON (Reuters) - International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment.